In the coal belt of Jharia, Jharkhand, men emerge from pits with blackened faces and a cough that never fully clears. They report breathlessness climbing slopes, carrying tools, or simply walking to the market. Many have worked underground for decades. Some have lost brothers or fathers to what locals call "the miner's disease." Yet when they seek care at government health centres, the spirometry machines—the gold standard for diagnosing obstructive lung disease—sit uncalibrated, gathering dust. A machine that could detect early airway obstruction instead produces numbers no clinician trusts. The result: years of symptomatic treatment, missed opportunities for prevention, and a slow progression toward respiratory failure.

This is not a story of ignorance or neglect alone. It is a story of calibration—a technical, financial, and systemic gap that separates a working diagnosis from a precise one. Across India, the same condition—occupational lung disease—plays out differently depending on setting. A Mumbai executive with breathlessness receives same-day spirometry and a tailored management plan. A Delhi slum dweller waits months for a test. A Jharia miner may never receive one at all. The underlying biology is the same; the system response is not.

The Calibration Gap: When the Gold Standard Rusts

The World Health Organization has flagged occupational lung disease as a rising burden globally, particularly in low- and middle-income countries where mining and construction employ millions. In India, the National Institute of Occupational Health estimates that roughly 3 million workers are exposed to silica dust, with pneumoconiosis prevalence ranging from 3% to 54% across different mining regions. Jharia, one of India's oldest coalfields, sits at the epicentre of this crisis.

Miners report breathlessness for years before any formal diagnosis. Many are told they have asthma or chronic bronchitis. Some are prescribed inhalers that provide marginal relief. But without baseline lung function recorded—without a reliable spirometry reading—clinicians are essentially guessing. The machine that could clarify the picture is present in many clinics. But it is not calibrated.

Calibration is the process of verifying that a spirometer's volume and flow measurements are accurate. The American Thoracic Society recommends daily calibration checks using a 3-litre syringe. In Jharia, that syringe often costs roughly three months of a miner's wages. Many clinics have one, but it is lost, broken, or never purchased. Without it, the device drifts. A patient with significant obstruction may produce a reading that falls within the normal range—a false negative that delays diagnosis by three to five years.

The scale of the problem is hard to quantify because uncalibrated machines generate unreliable data. But anecdotal reports from community health workers suggest that in some blocks, fewer than one in ten spirometry attempts yield a valid result. The machine beeps, the printout emerges, but the numbers are meaningless. Miners leave with a slip of paper and no actionable information.

Spirometry as Gatekeeper: How the Test Shapes Diagnosis

Spirometry measures two key volumes: forced expiratory volume in one second (FEV1) and forced vital capacity (FVC). The ratio FEV1/FVC defines airflow obstruction. A ratio below 0.70, after bronchodilator, is the classic threshold for COPD. In occupational lung disease, the pattern can be mixed—restriction from fibrosis, obstruction from bronchitis, or both. The test is simple in concept: take a deep breath, seal your lips around the mouthpiece, and blast out as hard and fast as you can for at least six seconds. But the devil is in the execution.

A patient must give maximal effort. The technician must coach effectively. The device must be accurate. If the spirometer is uncalibrated, even a perfect effort yields flawed numbers. A drift of 50 mL in volume measurement can shift a borderline ratio from abnormal to normal. Over years of annual screening, that drift accumulates, masking progression.

In Jharia, the consequences are stark. Miners with early pneumoconiosis—small opacities on chest X-ray, but preserved lung function—are told they are fine. They continue working. By the time breathlessness becomes disabling, the disease has often advanced to progressive massive fibrosis, where large scarred masses replace lung tissue. At that stage, no treatment reverses the damage. Oxygen therapy and lung transplantation are the only options, and neither is accessible to most miners.

The test also shapes treatment decisions. Inhaled bronchodilators and corticosteroids are effective for asthma and COPD, but they do not halt fibrotic progression. Without accurate spirometry, clinicians may prescribe the wrong drugs, wasting scarce resources and exposing patients to side effects. A miner with pneumoconiosis may be treated for asthma for years before the correct diagnosis emerges—if it ever does.

The Biology of Dust: What Coal Does to Alveoli

To understand the stakes, it helps to trace the path of a dust particle. When a miner inhales coal dust—a mixture of carbon, silica, and other minerals—the particles travel down the trachea, through branching bronchi, and into the alveoli, the tiny air sacs where gas exchange occurs. The lungs' first line of defence is the macrophage, a scavenger cell that engulfs the particle. But coal dust is not easily digested. The macrophage dies, releasing cytokines—chemical signals that summon more immune cells. Inflammation sets in.

Repeated exposure leads to chronic inflammation. Fibroblasts deposit collagen, scarring the delicate alveolar walls. This is pneumoconiosis: a restrictive lung disease that stiffens the lungs, making it harder to expand them with each breath. The patient feels breathless because their lungs cannot fully inflate. In advanced cases, large masses of scar tissue—progressive massive fibrosis—distort the lung architecture, pulling airways open or compressing them.

Silica, a component of coal dust, is particularly dangerous. It causes silicosis, a fibrotic disease that can progress even after exposure stops. The immune response to silica is relentless: macrophages engulf the particles, release reactive oxygen species, and trigger apoptosis. The cycle of death and inflammation continues, scarring lung tissue over years. CT scans reveal nodular opacities that are invisible on chest X-ray in early stages. But CT is rarely available in Jharia's primary health centres.

The biology does not discriminate by income. A miner's alveoli respond the same way as an executive's. But the executive's exposure is short-lived—a construction site, a sandstorm—while the miner's is daily, for decades. The dose makes the disease.

System Failure: Why Machines Stay Broken

Why do spirometers in Jharia remain uncalibrated? The answer is a cascade of failures. First, there is no technician within 200 kilometres of some mining blocks who is trained to perform calibration. The district hospital may have a respiratory therapist, but he or she is responsible for a population of half a million. Calibration is a five-minute task if the syringe is available, but it is not prioritised.

Second, the calibration syringe itself costs roughly 8,000 to 12,000 rupees—three months' wages for a miner earning 3,000 rupees per month. Government procurement contracts often favour cheap spirometers that meet only the minimum standards. The syringe is considered an accessory, not a consumable. When it is lost, it is not replaced.

Third, power outages are frequent in Jharia. Many spirometers are electronic; voltage fluctuations corrupt their internal calibration. A machine that was accurate in the morning may drift after a surge. Without a daily check, the error accumulates. Some clinics have resorted to using handheld mechanical spirometers that do not require electricity, but these too need periodic calibration with a syringe.

Fourth, there is no accountability. The doctor who orders the test may not know the machine is uncalibrated. The technician who performs it may not have the authority to demand a new syringe. The district health officer may not have the budget. The result is a system where the tool exists but the function is broken. Miners who can afford it travel to private labs in Dhanbad or Ranchi, paying out-of-pocket for a reliable test. Those who cannot, go undiagnosed.

The Wealth Gradient: Breathlessness Across Settings

Compare the Jharia miner to a patient in a Mumbai corporate hospital. The executive with breathlessness is seen within a week. Spirometry is performed by a trained technician, with daily calibration logs available for review. If the test suggests obstruction, a bronchodilator reversibility test is done immediately. Within an hour, the patient has a diagnosis: asthma, COPD, or something else. Treatment begins the same day.

In a Delhi slum, the picture is different. A public hospital may have one spirometer for an entire respiratory ward. Patients wait months for an appointment. When their turn comes, the machine may be out of service. If it works, the technician has 15 minutes per patient—not enough to coach a maximal effort. Effort-dependent tests yield variable results. A patient with mild obstruction may be told they are normal. Another with normal lungs but poor effort may be labelled as obstructed.

Private clinics in cities offer handheld spirometers that connect to smartphones. These devices are cheaper and easier to calibrate, but their accuracy varies. A 2023 study in the Indian Journal of Chest Diseases compared a popular handheld device to a laboratory spirometer and found a mean FEV1 difference of 120 mL—enough to misclassify a patient with borderline obstruction. Yet for many, these devices are the only option.

Wealth buys diagnosis, but not cure. Even in Mumbai, the executive with silicosis from a brief construction exposure faces the same fibrotic progression as the Jharia miner. The difference is that the executive knows what they have. They can avoid further exposure, monitor decline, and plan for disability. The miner works on, unaware, until the disease is advanced.

What a Calibrated Machine Would Change

If every spirometer in Jharia were calibrated daily, what would change? Early detection would become possible. A miner with FEV1 decline of 60 mL per year—twice the normal rate—could be identified and counselled to reduce dust exposure. In high-income countries, annual spirometry screening of coal miners has been shown to cut progression to massive fibrosis by roughly 40%, because workers are moved to low-exposure roles before irreversible damage occurs.

The fix is not technologically complex. Training one technician per district to perform daily calibration costs roughly 5,000 rupees per session. A 3-litre syringe costs 10,000 rupees and lasts years. Tele-spirometry pilots, where a technician in a remote clinic connects to a pulmonologist in a city for real-time quality review, have shown promise in small studies. The Indian Council of Medical Research has funded a pilot in three districts, but Jharia is not yet included.

Miners' unions have begun demanding mandatory calibration logs in health centres. In 2025, the Jharia Koyla Mazdoor Union submitted a memorandum to the district magistrate listing 12 health centres where spirometers were non-functional. The response, according to union leaders, was a promise to inspect—but no action has been reported. The gap between policy and practice remains wide.

Yet even with calibration, challenges remain. Spirometry requires patient effort. Illiterate miners may not understand the instructions. Language barriers, cultural norms around breathing tests, and fear of losing wages if diagnosed all complicate uptake. A calibrated machine is necessary but not sufficient. It must be paired with trained counsellors, worker education, and a system that protects miners from retaliation if they report breathlessness.

Trade-Offs and Counter-Arguments: Is Calibration Enough?

Some health policy experts argue that focusing on spirometry calibration alone may divert attention from broader preventive measures. For instance, dust suppression technologies—such as water sprays, ventilation improvements, and personal protective equipment—could reduce the incidence of lung disease more effectively than any diagnostic tool. A 2022 analysis by the International Labour Organization estimated that in mines with adequate dust control, pneumoconiosis rates dropped by roughly 60% over a decade, compared to minimal change in mines without such measures. The argument is that prevention, not detection, should be the priority.

However, this framing sets up a false choice. Calibration and prevention are complementary, not competitive. Even with the best dust control, some miners will develop disease due to historical exposure or occasional breaches in protection. Spirometry serves as a surveillance tool to identify those at risk before irreversible damage occurs. Moreover, a calibrated machine can help evaluate the effectiveness of dust control measures by tracking population-level lung function trends. Without reliable data, managers cannot know whether their interventions are working.

Another counter-argument is that spirometry is too operator-dependent for low-resource settings. Proponents of alternative screening tools, such as peak flow meters or symptom questionnaires, argue that these simpler methods could reach more miners at lower cost. Peak flow meters cost around 500 rupees and require minimal training. However, they measure only peak expiratory flow, which correlates poorly with FEV1 in restrictive lung diseases like pneumoconiosis. A miner with early fibrosis may have normal peak flow but reduced FVC, leading to false reassurance. Symptom questionnaires, such as the St. George's Respiratory Questionnaire, have been validated in Indian populations but rely on self-reporting, which can be influenced by fear of job loss. In a 2021 study in Jharia, nearly 40% of miners with breathlessness on exertion denied symptoms when asked by their employer's clinic. Spirometry provides an objective measure that cannot be easily faked.

Global Comparisons: Lessons from Other Mining Regions

Jharia is not alone in facing this calibration gap. In South Africa's gold mines, similar challenges have been documented. A 2019 study in the South African Medical Journal reported that 30% of spirometers in rural clinics had not been calibrated in the previous six months. The country's Mine Health and Safety Council responded by deploying mobile calibration units that travel to remote clinics quarterly. Within two years, the proportion of valid spirometry tests rose from 60% to 85%. The cost per test was roughly 50 rand (about 250 rupees)—a fraction of the cost of treating advanced silicosis.

In China, where coal mining employs over 5 million workers, the government mandated annual spirometry for all miners in 2015. However, enforcement has been uneven. A 2023 report from the Chinese Center for Disease Control found that only 40% of mines in Shanxi province had functional calibration equipment. The report recommended integrating spirometry calibration into the national occupational health inspection system, with penalties for non-compliance. Early results from pilot districts showed that when calibration was tied to licensing, compliance exceeded 90%.

These examples suggest that systemic solutions—mobile units, regulatory mandates, and financial accountability—can close the calibration gap. They also highlight that the problem is not unique to India, but reflects a global failure to prioritize diagnostic quality in occupational health. In Jharia, the path forward may involve a combination of these approaches, adapted to local constraints.

This article is for informational purposes only and does not constitute medical advice. Readers with respiratory symptoms should consult a qualified healthcare provider.